Olympus, Gore, and ConMed Collaborate for GORE® VIABIL® Biliary Device Support Transition
In a significant development within the medical technology industry, Olympus Corporation, W. L. Gore & Associates, and ConMed Corporation have announced a strategic transition regarding the commercial support and distribution of the GORE® VIABIL® Biliary Endoprosthesis in the United States. This transition will become effective on January 1, 2026, when Olympus will take over as the exclusive distributor of the VIABIL® device, which has been recognized for its role in alleviating complications arising from biliary strictures.
Until the end of 2025, ConMed will continue to support the VIABIL® device completely, ensuring that healthcare providers have uninterrupted access to this critical technology. The collaborative approach of these three companies emphasizes their shared commitment to maintaining a high standard of care in the treatment of biliary complications, crucial for healthcare professionals and patients alike.
The GORE® VIABIL® device is a fully covered self-expanding metal stent that provides a reliable alternative for relieving the symptoms associated with biliary strictures. Biliary strictures can occur due to various reasons, including cancer, injury, and other medical conditions, and often result in a significant impact on the patient's quality of life. The effective management of these strictures is pivotal in improving patient outcomes, and the introduction of the VIABIL® device has been a step forward in this area.
Olympus, known for its innovative medical technologies, focuses on enhancing healthcare outcomes worldwide through pioneering products and solutions. For over a century, the company has made substantial contributions to the medical field by delivering technologies that enhance diagnoses and treatments. In taking over the distribution of the VIABIL® device, Olympus aims to further its goal of improving patient health by providing seamless access to advanced medical devices.
ConMed Corporation, distinguished for its medical equipment pivotal in various surgical procedures, will remain committed to supporting healthcare professionals until the transition is complete. With an extensive product line that crosses multiple specialties, ConMed’s expertise in ensuring that devices reach those in need underscores the importance of collaboration in health technology solutions.
W. L. Gore, renowned for its innovation in materials science since 1958, has successfully addressed complex technical challenges, significantly in the realms of biocompatibility and device functionality. As the current distributor of the VIABIL® device, Gore's involvement in the transition reflects its dedication to advancing healthcare technology and providing solutions that have transformative impacts on patient lives.
All three entities are committed to facilitating a smooth distribution transition. Representatives from Olympus, Gore, and ConMed are available to clarify future processes and assist healthcare providers and patients during this transition phase. This cooperative effort illustrates a profound understanding of the critical nature of comprehensive care and its implications in the medical ecosystem.
Continual access to the GORE® VIABIL® device will enable healthcare providers to maintain high standards of care for their patients, reinforcing the collaborative ethos that is foundational in this industry. As the date for the transition approaches, stakeholders can expect ongoing communication and resources to facilitate this change, ensuring a streamlined process without disruptions to patient care. For further inquiries, healthcare professionals can contact representatives from Olympus starting from January 2026.
In summary, the transition of the GORE® VIABIL® biliary endoprosthesis distribution signifies a strategic partnership aimed at elevating care standards in the face of biliary disorders. Patients and providers alike can anticipate seamless support and access to this life-enhancing technology through this collaborative initiative that prioritizes excellent patient outcomes across healthcare settings.
Until the end of 2025, ConMed will continue to support the VIABIL® device completely, ensuring that healthcare providers have uninterrupted access to this critical technology. The collaborative approach of these three companies emphasizes their shared commitment to maintaining a high standard of care in the treatment of biliary complications, crucial for healthcare professionals and patients alike.
The GORE® VIABIL® device is a fully covered self-expanding metal stent that provides a reliable alternative for relieving the symptoms associated with biliary strictures. Biliary strictures can occur due to various reasons, including cancer, injury, and other medical conditions, and often result in a significant impact on the patient's quality of life. The effective management of these strictures is pivotal in improving patient outcomes, and the introduction of the VIABIL® device has been a step forward in this area.
Olympus, known for its innovative medical technologies, focuses on enhancing healthcare outcomes worldwide through pioneering products and solutions. For over a century, the company has made substantial contributions to the medical field by delivering technologies that enhance diagnoses and treatments. In taking over the distribution of the VIABIL® device, Olympus aims to further its goal of improving patient health by providing seamless access to advanced medical devices.
ConMed Corporation, distinguished for its medical equipment pivotal in various surgical procedures, will remain committed to supporting healthcare professionals until the transition is complete. With an extensive product line that crosses multiple specialties, ConMed’s expertise in ensuring that devices reach those in need underscores the importance of collaboration in health technology solutions.
W. L. Gore, renowned for its innovation in materials science since 1958, has successfully addressed complex technical challenges, significantly in the realms of biocompatibility and device functionality. As the current distributor of the VIABIL® device, Gore's involvement in the transition reflects its dedication to advancing healthcare technology and providing solutions that have transformative impacts on patient lives.
All three entities are committed to facilitating a smooth distribution transition. Representatives from Olympus, Gore, and ConMed are available to clarify future processes and assist healthcare providers and patients during this transition phase. This cooperative effort illustrates a profound understanding of the critical nature of comprehensive care and its implications in the medical ecosystem.
Continual access to the GORE® VIABIL® device will enable healthcare providers to maintain high standards of care for their patients, reinforcing the collaborative ethos that is foundational in this industry. As the date for the transition approaches, stakeholders can expect ongoing communication and resources to facilitate this change, ensuring a streamlined process without disruptions to patient care. For further inquiries, healthcare professionals can contact representatives from Olympus starting from January 2026.
In summary, the transition of the GORE® VIABIL® biliary endoprosthesis distribution signifies a strategic partnership aimed at elevating care standards in the face of biliary disorders. Patients and providers alike can anticipate seamless support and access to this life-enhancing technology through this collaborative initiative that prioritizes excellent patient outcomes across healthcare settings.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.